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however, median overall survival (OS) analyses do not adequately capture this type 
of prolonged survival effect. Therefore, additional value metrics are necessary to 
completely describe ipilimumab’s survival impact in treatment-naïve metastatic 
melanoma patients vs other anti-cancer agents. Methods: We conducted a lit-
erature review of trial data supporting approval of agents for various metastatic 
cancers within the last 10 years. Metrics included primary/secondary OS, median 
OS at approval, and Kaplan-Meier (KM) survival curves. Each agent was plotted, with 
x-axis reflecting total drug cost and y-axis reflecting improvement vs comparator 
for median and mean OS (area under KM curve), 1-year survival, and 1-year number 
needed to treat (NNT) to avoid 1 death. A line indicating an average cost-to-benefit 
ratio identified agents with highest relative value per metric. Ipilimumab (3-mg/
kg monotherapy) pooled phase II/III data from chemotherapy-naïve patients were 
assessed within this value metric portfolio. Results: Ipilimumab demonstrated 
high relative median OS improvement vs comparator (48.4% [0.3%–63.3% with other 
agents]), the greatest absolute and relative mean OS improvements (6.9 months 
[0.2–6.4 months with other agents]; 60.1% [1.3%–34.3% with other agents]), the great-
est relative 1-year survival improvement amongst first-line agents (41.9% [4.2%–
38% with other agents]), and the lowest NNT (5 patients [6–66 with other agents]). 
Ipilimumab’s high relative value was confirmed when plotting each drug’s clinical 
performance vs total drug costs. ConClusions: Using relevant survival metrics, 
ipilimumab demonstrates high relative value within a value metric portfolio in 
metastatic diseases. Long-term survival data for other agents for metastatic cancers 
are not yet available to estimate ipilimumab’s long-term relative value.
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objeCtives: Capecitabine (C), gemcitabine (G) and vinorelbine (V) are commonly 
used as single agents in patients with MBC. Eribulin (E) is among the most recent 
cytotoxic agents to gain regulatory approval for MBC in the United States (U.S.) as 
a single agent. In this analysis, toxicity and supportive care use was compared 
between the four agents in a sample of MBC patients treated in a U.S. community 
oncology setting. Methods: 411 patients (C= 144, G= 181, V= 96 and E= 90) who were 
treated in 19 community oncology clinics over the preceding two year period were 
identified. Data collection included baseline patient and disease characteristics, 
duration of therapy, supportive care, type of dose limiting toxicities and their impact 
on overall health care resource use. Results: The proportion of patients reporting 
at least one adverse event (any grade) with C, G, V and E was 45%, 65%, 75% and 63%. 
The most common toxicities with C, G and V were diarrhea (19.4%), anemia (34.6%) 
and neutropenia (50.0%). The most common toxicity for E was neutropenia (32.2%). 
Overall, 5.6%, 19.8%, 22.9% and 22.2% of patients receiving C, G, V and E required at 
least one medical intervention to manage a toxic event. Blood transfusions were 
most prevalent with G (12.3%) and V (13.5%). In contrast, unplanned clinic visits 
were most common with E (7.8%) and C (2.1%). Colony stimulating factor support 
was significantly higher with V (100%) relative to E (84.4%), G (72.9%) and C (63.9%) 
respectively (p < 0.01). However, toxicity was the cause of treatment discontinuation 
in significantly more patients receiving C (25.7%) compared to 8.6%, 11.5% and 8.9% 
of G, V and E patients (p < 0.05). ConClusions: Significantly more patients receiv-
ing V required support with high cost colony stimulating factors. Capecitabine had 
less neutropenia and anemia, but more treatment discontinuations due to toxicity.
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objeCtives: The aim of this systematic literature review is to evaluate the safety 
and effectiveness of robot-assisted surgery (RAS) and conventional laparoscopic 
rectal surgery (CLS) for rectal cancer. Methods: We performed a systematic review 
of available literature. Three international databases (OvidMedline, Ovid EMBASE, 
Cochrane Central Rgister of Controlled Trials) and six Korean databases were used 
in searching for existing literature. The PICO and the search strategy were deter-
mined through consultation with a methodologist and a clinician. 1,664 studies 
were found at first. The final selection was made after removing duplicates and 
applying the inclusion and exclusion criteria established beforehand. The Cochrane 
Risk of Bias (RoB) was used for randomized clinical trial and the Methodological 
index for non-randomized (MINORS) for observational (cohort and case-control) 
studies were utilized for evaluating the quality of literature. Results: 15 two-arms 
studies involving 1,876 patients were finally included. RAS was associated with a 
lower rate of intraoperative conversion than CLS (RR= 0.29, 95% CI= 0.15-0.56). The 
operating time was higher for RAS (MD= 43.14, 95% CI= 18.25-68.02, I2= 95%), but only 
the directional nature could be determined due to the heterogeneity of literature. 
The RAS had a higher number of lymph node extraction (MD= 0.88, 95% CI= 0.00-
1.75) and the time to first flatus was short (MD= 0.14, 95% CI= -0.28-0.00). However, 
this difference does not indicate a significant clinical difference. ConClusions: 
RAS was associated with a lower intraoperative conversion rate than CLS, with no 
differences in complication rate as surrogate markers of successful surgery.
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although a variety of options were available on the market for 3rd-line mCRC treat-
ments, there is no conclusive evidence for an optimal choice in therapy. The difference 
in OS among chemotherapy backbones was not significant (log-rank test, p= 0.06), 
whether they were targeted therapies or not. Novel and newly approved treatments 
may provide further benefit for mCRC patients continuing on 3rd-line therapy.
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objeCtives: In recent years, the treatment landscape in nsNSCLC has changed; 
new therapies (e.g. bevacizumab (BEV) indicated in 1L) have become available and 
other therapies (e.g. pemetrexed (PEM) in 1L and 2L) moved into earlier lines in the 
treatment paradigm. While there has been an expansion of the available treat-
ment options, it is unclear how the therapy sequence rank in terms of best PFS 
for patients with nsNSCLC. Methods: A therapy sequencing disease model that 
approximates treatment outcomes in up to five lines of treatment was developed 
for patients with nsNSCLC. The primary source of data for PFS and time to death 
was published pivotal trial data. All patients were treatment-naïve and in the 
PFS state, receive first-line treatment with either BEV-based therapy or doublet 
chemotherapy (including the option of pemetrexed + cisplatin (PEM+CIS)). Patients 
would then progress to a subsequent line therapy, remain in PFS or die. In case of 
progression, it was assumed that each survivor would receive a subsequent line 
of therapy (based on EMA licensed therapies). Weibull distribution curves were 
fitted to the data. Results: All BEV-based first-line therapy sequences analyzed 
achieved total PFS of more than 15 months. Bevacizumab-carboplatin-paclitaxel (1L) 
à pemetrexed (2L) à erlotinib (3L) à docetaxel (4L) resulted in total mean PFS time 
of 15.5 months, for instance. Sequences including PEM+CIS in first-line achieved 
total PFS times between 12.3 and 13.3 months with potentially (slightly) higher 
total PFS time achieved when assuming PEM continuation therapy in maintenance 
after PEM+CIS in 1L induction. ConClusions: The model suggests that treatment 
sequencing strategies starting with a BEV-based combination in 1L yield better PFS 
outcomes than those starting with PEM-based combinations due to the possibility 
of one further-line treatment starting with BEV-based combination.
PCN14
A PhArmACoeCoNomiC APPrAisAl of CABAziTAxel versus ABirATeroNe 
for The seCoNd-liNe TreATmeNT of PATieNTs wiTh meTAsTATiC 
hormoNe-refrACTory ProsTATe CANCer (mhrPC) ProgressiNg AfTer The 
TreATmeNT wiTh doCeTAxel: A sysTemATiC review
Bektur C., Nurgozhin T.
Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan
objeCtives: Currently,there are two drugs recommended by EAU for the second-
line treatment of mHRPC after docetaxel-based therapy:cabazitaxel and abiraterone 
acetate. The purpose of this study was to evaluate the available data on effective-
ness, safety and major pharmacoeconomic aspects of cabazitaxel and abiraterone 
for the treatment of patients with mHRPC progressing after the treatment with doc-
etaxel. Methods: Relevant publications were identified using a predefined search 
strategy on major academic databases (MEDLINE, EMBASE, Cochrane Library) and 
conference proceedings. Articles and documents published in English and Russian 
languages between January2010 and December2013 were accepted for the full text 
evaluation. Data(study characteristics and end points/results) was extracted and 
summarized from eligible articles accepted according to the applied inclusion and 
exclusion criteria. Results: 63 articles were accepted for the full text evaluation 
from 331 identified abstracts from primary search of databases. 17 full-text publi-
cations were included in the data extraction after meeting the predefined criteria. 
59% of these publications were regarding the effectiveness and safety of drugs. The 
abiraterone treatment resulted in a higher median overall survival (15,8 months, 
95% CI, 14,8–17,0) than the therapy with cabazitaxel (15,1 months, 95% CI, 14,1–16,3). 
Moreover, median progression-free survival (median time to PSA progression) was 
8.5 (95% CI 8,3–11,1) and 2.8 (95% CI 2,4–3,0) months, respectively. Overall, abira-
terone has a better toxicity profile than cabazitaxel, the most common grade 3-4 
adverse effects for abiraterone was fatigue(9%) and anaemia(8%), and for cabazitaxel 
they were neutropenia(82%) and diarrhea(6%). Abiraterone was more cost-effective 
compared to placebo ($94 -123.4K/QALY) than cabazitaxel compared to placebo 
($149 - 163.2K/QALY), according to 4 identified articles with CEA. ConClusions: 
The results of present review show that abiraterone is a more favourable option for 
the second-line treatment of patients with mHRPC progressing after the docetaxel-
based treatment than cabazitaxel in terms of safety and cost-effectiveness.
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objeCtives: Payers, patients, and clinical decision-makers expect value from 
innovative anti-cancer agents. Ipilimumab, an anti–CTLA-4 monoclonal antibody, 
has been shown to provide durable long-term survival for a proportion of unre-
sectable/metastatic melanoma patients, with follow-up in some out to 10 years; 
